PT - JOURNAL ARTICLE AU - Elle M. Weeks AU - Jacob C. Ulirsch AU - Nathan Y. Cheng AU - Brian L. Trippe AU - Rebecca S. Fine AU - Jenkai Miao AU - Tejal A. Patwardhan AU - Masahiro Kanai AU - Joseph Nasser AU - Charles P. Fulco AU - Katherine C. Tashman AU - Francois Aguet AU - Taibo Li AU - Jose Ordovas-Montanes AU - Christopher S. Smillie AU - Moshe Biton AU - Alex K. Shalek AU - Ashwin N. Ananthakrishnan AU - Ramnik J. Xavier AU - Aviv Regev AU - Rajat M. Gupta AU - Kasper Lage AU - Kristin G. Ardlie AU - Joel N. Hirschhorn AU - Eric S. Lander AU - Jesse M. Engreitz AU - Hilary K. Finucane TI - Leveraging polygenic enrichments of gene features to predict genes underlying complex traits and diseases AID - 10.1101/2020.09.08.20190561 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.08.20190561 4099 - http://medrxiv.org/content/early/2020/09/10/2020.09.08.20190561.short 4100 - http://medrxiv.org/content/early/2020/09/10/2020.09.08.20190561.full AB - Genome-wide association studies (GWAS) are a valuable tool for understanding the biology of complex traits, but the associations found rarely point directly to causal genes. Here, we introduce a new method to identify the causal genes by integrating GWAS summary statistics with gene expression, biological pathway, and predicted protein-protein interaction data. We further propose an approach that effectively leverages both polygenic and locus-specific genetic signals by combining results across multiple gene prioritization methods, increasing confidence in prioritized genes. Using a large set of gold standard genes to evaluate our approach, we prioritize 8,402 unique gene-trait pairs with greater than 75% estimated precision across 113 complex traits and diseases, including known genes such as SORT1 for LDL cholesterol, SMIM1 for red blood cell count, and DRD2 for schizophrenia, as well as novel genes such as TTC39B for cholelithiasis. Our results demonstrate that a polygenic approach is a powerful tool for gene prioritization and, in combination with locus-specific signal, improves upon existing methods.Competing Interest StatementJ.C.U reports compensation from consulting services with Goldfinch Bio and AVROBIO. R.S.F. is an employee of Vertex Pharmaceuticals. C.P.F. is an employee of Bristol Myers Squibb. J.O.M. reports compensation for consulting services with Cellarity. A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and was an SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov until July 31, 2020. From August 1, 2020, A.R. is an employee of Genentech. J.N.H. served on the Scientific Advisory Board of and consults for Camp4 Therapeutics. E.S.L. serves on the Board of Directors for Codiak BioSciences and Neon Therapeutics, and serves on the Scientific Advisory Board of F-Prime Capital Partners and Third Rock Ventures; he is also affiliated with several non-profit organizations including serving on the Board of Directors of the Innocence Project, Count Me In, and Biden Cancer Initiative, and the Board of Trustees for the Parker Institute for Cancer Immunotherapy. He has served and continues to serve on various federal advisory committees.Funding StatementThis research was conducted using the UK Biobank Resource under project 31063. H.K.F. was funded by NIH grant DP5 OD024582 and by Eric and Wendy Schmidt. J.M.E. was supported by a Pathway to Independence Award (K99HG00917 and R00HG009917), the Harvard Society of Fellows, and the Base Research Initiative at Stanford University. J.M. and J.N.H. were supported by NIH grant R01DK075787. R.S.F. was supported by NHGRI NIH F31HG009850. J.O.M was supported by the Richard and Susan Smith Family Foundation, the HHMI Damon Runyon Cancer Research Foundation Fellowship (DRG-2274-16), the AGA Research Foundation's AGA-Takeda Pharmaceuticals Research Scholar Award in IBD AGA2020-13-01, the HDDC Pilot and Feasibility P30 DK034854, and the Food Allergy Science Initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA repository of processed gene features, visualizations of top derived features, and code to reproduce these analyses are available on GitHub at https://github.com/FinucaneLab/gene_features. Complete PoPS results for 95 complex traits in the UK Biobank and 18 additional disease traits as well as results for PoPS and locus-based methods in genome-wide significant loci are available at https://www.finucanelab.org/data.